Biodistribution and radiation dosimetry of [11C]raclopride in healthy volunteers

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 8, 2005, Pages 952-958

  Ribeiro, Maria João ^a   Ricard, Marcel ^b   Bourgeois, Sandrine ^a   Lièvre, Marie Angele ^a   Bottlaender, Michel ^a   Gervais, Philippe ^a   Dollé, Frédéric ^a   Syrota, André ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

11C raclopride; Dopamine D2 receptors; Dosimetry; PET

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; RACLOPRIDE; RACLOPRIDE C 11; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLADDER; BLOOD ANALYSIS; BLOOD PRESSURE; BRAIN; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; ELECTROCARDIOGRAM; GALLBLADDER; HUMAN; HUMAN CELL; INTESTINE; KIDNEY; LIVER; LUNG; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; RADIATION ABSORPTION; RADIATION DOSE; VENOUS BLOOD;

ADULT; BODY BURDEN; BRAIN; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; RACLOPRIDE; RADIATION DOSAGE; RADIOPHARMACEUTICALS; REFERENCE VALUES; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 23944477431     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1783-2     Document Type: Article

References (34)

1. Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedstrom CG, et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A 1985;82:3863-7.
2. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231:258-61.
3. Halldin C, Farde L, Hall H, Hogberg T, Printz G, Pulka W, et al. Synthesis of five benzamide analogs: comparison with positron emission tomography. Acta Radiol Suppl 1991;376:121-2.
4. 11C]-raclopride. Ann N Y Acad Sci 1993;695:81-5.
5. 11C]raclopride. J Cereb Blood Flow Metab 1993;13:310-4.
6. 18F-N-methylspiroperidol. Psychiatry Res 1996;67:11-6.
7. Wang GJ, Volkow ND, Fowler JS, Logan J, Gur R, Netusil N, et al. Age associated decrements in dopamine D2 receptors in thalamus and in temporal insula of human subjects. Life Sci 1996;59:PL31-5.
8. 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-92.
9. Antonini A, Vontobel P, Psylla M, Gunther I, Maguire PR, Missimer J, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995;52:1183-90.
10. 11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 1998;43:253-5.
11. Hilker R, Klein C, Ghaemi M, Kis B, Strotmann T, Ozelius LJ, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial Parkinsonism associated with mutations in the Parkin gene. Ann Neurol 2001;49:367-76.
12. 11C]raclopride. Mov Disord 1997;12:33-8.
13. Rinne JO, Laihinen A, Rinne UK, Nagren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord 1993;8:134-8.
14. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997;120:503-14.
15. 11C-raclopride. Psychopharmacology (Berl) 1993;112:308-14.
16. Nyberg S, Farde L, Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997;16:1-7.
17. 11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Res 1998;82:147-60.
18. 11C]raclopride binding in human brain. Clin Positron Imaging 1999;2:205-9.
19. 11C] raclopride. Neuropsychopharmacology 2002;27:248-59.
20. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000;152:174-80.
21. 11C]methyl triflate. J Label Compd Radiopharm 1999;42:1183-93.
22. Watson CC, Newport D, Casey ME, deKemp RA, Beanlands RS, Schmand M,et al. Evaluation of simulation-based scatter correction for 3D PET cardiac imaging. IEEE Trans Nucl Sci 1997;44:90-7.
23. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imag 1994;13:601-9.
24. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculationsThe Society of Nuclear Medicine-New York, NYLoevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. The Society of Nuclear Medicine, New York, NY, 1991.
25. Cristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photons sources. ORNL Report ORNL/TM-8381 V1-V7Oak Ridge National LaboratoryOak Ridge, TNCristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photons sources. ORNL Report ORNL/TM-8381 V1-V7. Oak Ridge, TN: Oak Ridge National Laboratory; 1987.
26. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538-46.
27. ICRP Publication 60: Recommendations of the International Commission on Radiological Protection. Ann ICRP 1991;21:493-502.
28. ICRP Publication 80: Radiation dose to patients from radiopharmaceuticals. Addendum 2 to ICRP Publication 53. Ann ICRP 1998;28:1-126.
29. Herscovitch P, Schmall B, Doudet DJ, Carson RE, Eckelman WC. Biodistribution and radiation dose estimates for [C-11]raclopride. J Nucl Med 1997;38:224P.
30. 11C] methionine using whole-body positron emission tomography. Eur J Nucl Med 1998;25:629-33.
31. Beekhuis H. Population radiation absorbed dose from nuclear medicine procedures in the Netherlands. Health Physics 1988;54:287-91.
32. ICRP Publication 62: Radiological protection in biomedical research. Ann ICRP 1991;22:1-28.
33. Billon S, Morin A, Caer S, Baysson H, Gambard JP, Rannou A, et al. Evaluation de l'exposition de la population française à la radioactivité naturelle. Radioprotection 2004;39:213-32.
34. Balanov MI, Krisyuk EM, Ramel C. Environmental radioactivity, population exposure and related health risks in the east Baltic region. Scand J Work Environ Health 1999;25:17-32.